

Literatur für onkologie heute 06/2021

SCHWERPUNKT: LYMPHOME

Diffus großzelliges B-Zell-Lymphom: Aktuelle Entwicklungen in Diagnostik und Therapie (S. 27–33)

B. Glaß

1. Cheson BD et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol* 2014; 32(27): 3059–68
2. Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* 2002; 346(4): 235–42
3. Cunningham D et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. *Lancet* 2013; 381(9880): 1817–26
4. Pfreundschuh M et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MINT) Group. *Lancet Oncol* 2011; 12(11): 1013–22
5. Pfreundschuh M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). *Lancet Oncol* 2008; 9(2): 105–16
6. Stiff PJ et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. *N Engl J Med* 2013; 369(18): 1681–90
7. Schmitz N et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). *Lancet Oncol* 2012(12): 1020–45
8. Fitoussi O et al. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. *Haematologica* 2011; 96(8): 1136–43
9. Poeschel V et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. *Lancet* 2020; 394(10216): 2271–81
10. Peyrade F et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. *Lancet Oncol* 2011; 12(5): 460–8
11. Held G et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. *J Clin Oncol* 2013; 31(32): 4115–22
12. Michael Pfreundschuh NM et al. RADIOTHERAPY TO BULKY AND EXTRALYMPHATIC DISEASE IN COMBINATION WITH 6XR-CHOP-14 OR R-CHOP-21 IN YOUNG GOOD-PROGNOSIS DLBCL PATIENTS: RESULTS OF THE 2X2 RANDOMIZED UNFOLDER TRIAL OF THE DSHNHL/GLA. *EHA Library*. 2018
13. Vellenga E et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. *Blood* 2008; 111(2): 537–43
14. Glass B et al. Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial. *Ann Oncol* 2017; 28(12): 3058–64
15. Borgerding A et al. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. *Annals of Hematology* 2010; 89(3): 283–9
16. Philip T et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. *N Engl J Med* 1995; 333(23): 1540–5

17. Crump M et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood* 2017; 130(16): 1800–8
18. Van Den Neste E et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. *Bone Marrow Transplant* 2016; 51(1): 51–7
19. Palanca-Wessels MC et al. Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. *The Lancet Oncology* 2015; 16(6): 704–15
20. Sehn LH et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *J Clin Oncol* 2020; 38(2): 155–65
21. Salles G et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. *Lancet Oncol* 2020; 21(7): 978–88
22. van der Horst HJ et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. *Blood Cancer J* 2021; 11(2): 38
23. Hutchings M et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. *J Clin Oncol*; 0(0):JCO.20.03175
24. Robinson SP et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. *Blood* 2002; 100(13): 4310–6
25. Glass B et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. *Lancet Oncol* 2014; 15(7): 757–66
26. Schuster SJ et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med* 2019; 380(1): 45–56
27. Neelapu SS et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med* 2017; 377(26): 2531–44
28. Nastoupil LJ et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. *J Clin Oncol* 2020; 38(27): 3119–28
29. Bartlett NL et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. *J Clin Oncol* 2019; 37(21): 1790–9
30. Duhrsen U et al. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. *J Clin Oncol* 2018; 36(20): 2024–34
31. Vitolo U et al. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. *J Clin Oncol* 2017; 35(31): 3529–37
32. Chiappella A et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. *Lancet Oncol* 2017; 18(8): 1076–88
33. Leonard JP et al. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. *J Clin Oncol* 2017; 35(31): 3538–46
34. Gisselbrecht C et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. *J Clin Oncol* 2010; 28(27): 4184–90
35. Crump M et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. *J Clin Oncol* 2014; 32(31): 3490–6
36. van Imhoff GW et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. *J Clin Oncol* 2016;JCO2016690198

Neue, zielgerichtete Therapiemöglichkeiten bei der chronischen lymphatischen Leukämie (S. 40–47)

M. A. Hoehstetter

1. Swerdlow SH et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood* 2016; 127(20): 2375–90
2. Barnes B et al. Bericht zum Krebsgeschehen in Deutschland 2016. Robert Koch-Institut, Berlin
3. Goldin LR et al. Familial aspects of chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis (MBL) and related lymphomas. *Eur J Clin Med Oncol* 2010; 2: 119–216
4. Cerhan JR, Slager SL. Familial predisposition and risk factors for lymphoma. *Blood* 2015; 125: 2265–73
5. Döhner H et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *N Engl J Med* 2000; 343: 1910–16
6. Landau DA et al. Mutations driving CLL and their evolution in progression and relapse. *Nature* 2015; 526: 525–30
7. Kipps TJ et al. Chronic lymphocytic leukemia. *Nat Rev Dis Primers* 2017; 3: 16096
8. Catera R, et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. *Mol Med* 2008; 14(11–12): 665–74
9. Seiler T et al. Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. *Blood* 2009; 114(17): 3615–24
10. Souers AJ et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. *Nat Med* 2013; 19(2): 202–08
11. Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. *Sem Cancer Biol* 2014; 24: 71–81
12. Hallek M et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood* 2018; 131(25): 2745–60
13. The International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. *Lancet Oncology*. 2016; 17(6): 779–90
14. Extermann M et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. *Crit Rev Oncol Hematol* 2004; 49: 69–75
15. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. Diagnostik, Therapie und Nachsorge für Patienten mit einer chronisch lymphatischen Leukämie. 2018 [29.08.2018]; https://www.awmf.org/uploads/tx_szleitlinien/018-032OLk_S3_Chronisch-lymphatische-Leukaemie_2018-04.pdf
16. Wendtner C-M et al. Chronische Lymphatische Leukämie (CLL) Onkopedia Leitlinie der DGHO. 2020. <https://www.onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@view/html/index.html>
17. Shanafelt TD et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. *N Engl J Med* 2018; 381: 432–43
18. Woyach JA et al. Ibrutinib regimens versus chemoimmunotherapy on older patients with untreated CLL. *N Engl J Med* 2018; 379: 2517–28
19. Sharman JP et al. Acalabrutinib with or without Obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. *Lancet* 2020; 395: 1278–91
20. Hallek M et al. First-Line Treatment with Fludarabine (F), cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group. *Lancet* 2010; 376: 1164–74

21. Stilgenbauer S et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. *Blood* 2014; 123: 3247–54
 22. Fischer K et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. *Blood* 2016; 127: 208–15
 23. Fischer K et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. *N Engl J Med* 2019; 380: 2225–36
 24. Burger JA et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *N Engl J Med* 2015; 373: 2415–37
 25. Byrd JC et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med* 2014; 371: 213–23
 26. Ghia P et al. ASCEND: Phase III, randomized trial of Acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. *J Clin Oncol* 2020; 38: 2849–61
 27. Stilgenbauer S et al. Venetoclax for patients with chronic lymphocytic leukemia with 17 deletion: results from the full population of a phase II pivotal trial. *J Clin Oncol* 2018; 36: 1973–80
 28. Seymour JF et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. *N Engl J Med* 2018; 1107–20
 29. Furman RR et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N Engl J Med* 2014; 997–1007
 30. Dreger P et al. Managing high-risk chronic lymphocytic leukemia during transition to a new treatment era: Stem cell transplantation or novel agents. A position statement of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT). *Blood* 2014; 124: 3841–49
-

PHARMAFORUM:

Seit einem Jahr bei Niedrigrisiko-MDS und Beta-Thalassämie zugelassen: Luspatercept kann Transfusionslast bei Patienten mit chronischer Anämie senken (S. 58–59)

1. Fachinformation Reblozyl®, aktueller Stand
2. Onkopedia-Leitlinie MDS; Stand: März 2021
3. Onkopedia-Leitlinie Beta Thalassämie; Stand: Oktober 2019
4. Suragani RN et al. *Nat Med* 2014; 20: 408–414
5. Paulson RF. *Nat Med* 2014; 20: 334–335
6. Dussiot M et al. *Nat Med* 2014; 20: 398–407
7. Fenaux P et al. *N Engl J Med* 2020; 382: 140–151
8. Cappellini MD et al. *N Engl J Med* 2020; 382: 1219–1231
9. Fenaux P et al. *ASH* 2019; Abstr. #841
10. Viprakasit V et al. *ASH* 2019; Abstr.#3545